Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by S C Pero
Combination Treatment With Grb7 Peptide and Doxorubicin or Trastuzumab (Herceptin) Results in Cooperative Cell Growth Inhibition in Breast Cancer Cells
British Journal of Cancer
Cancer Research
Oncology
Related publications
The Combination of NVP-BKM120 With Trastuzumab or RAD001 Synergistically Inhibits the Growth of Breast Cancer Stem Cells in Vivo
Oncology Reports
Medicine
Cancer Research
Oncology
Pharmacoeconomic Study of Herceptin® (Trastuzumab) for Breast Cancer Patients
Pharmacoeconomics: theory and practice
Trastuzumab in Combination With AT-101 Induces Cytotoxicity and Apoptosis in Her2 Positive Breast Cancer Cells
Future Oncology
Medicine
Cancer Research
Oncology
Treatment of HER-2/neu Overexpressing Breast Cancer Xenograft Models With Trastuzumab (Herceptin) and Gefitinib (ZD1839): Drug Combination Effects on Tumor Growth, HER-2/neu and Epidermal Growth Factor Receptor Expression, and Viable Hypoxic Cell Fraction
Clinical Cancer Research
Cancer Research
Oncology
Trastuzumab (Herceptin)
American Journal of Neuroradiology
Medicine
Nuclear Medicine
Neurology
Imaging
Radiology
Substituting Adjuvant Trastuzumab Emtansine for Herceptin Improves Survival in Patients With Human Epidermal Growth Factor Receptor 2–positive Breast Cancer
Cancer
Cancer Research
Oncology
Cooperative but Distinct Early Co-Signaling Events Originate From ERBB2 and ERBB1 Receptors Upon Trastuzumab Treatment in Breast Cancer Cells
Oncotarget
Oncology
The Telomerase Inhibitor Imetelstat Alone, and in Combination With Trastuzumab, Decreases the Cancer Stem Cell Population and Self-Renewal of HER2+ Breast Cancer Cells
Breast Cancer Research and Treatment
Cancer Research
Oncology
The Anti-erbB3 Antibody MM-121/SAR256212 in Combination With Trastuzumab Exerts Potent Antitumor Activity Against Trastuzumab-Resistant Breast Cancer Cells
Molecular Cancer
Cancer Research
Oncology
Molecular Medicine
